ClinicalTrials.Veeva

Menu

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC (MPSIIIC)

P

Phoenix Nest

Status

Enrolling

Conditions

Sanfilippo Syndrome Type C

Study type

Observational

Funder types

Industry
Other

Identifiers

NCT05825131
JLK-447

Details and patient eligibility

About

This study is planned to document, through retrospective and prospective data collection, syndrome progression in children and young adults with MPS IIIC.

Full description

This is a multi-center, natural history study of subjects with Sanfilippo syndrome type C or MPS IIIC. This study will combine a retrospective review of medical records and an ongoing collection of clinical data on an observational basis. Real-world data will be collected at home using a recording device.

Participants will be asked to attend clinic visits in person on a yearly basis. In clinic visits will include neurocognitive, developmental, behavioral, biochemical, imaging measures as well as retrospective medical record analysis.

At 6-month intervals between clinic visits, participants will be contacted remotely for some safety assessments (e.g., collecting information about concomitant medications, concurrent illnesses, and procedure-related adverse events [AEs] and serious AEs [SAEs] since last clinic visit).

At 6-month intervals, caregivers will complete questionnaires and record home video assessments using a dedicated, compliant study application (app) called C-RARE (Recording Application for Real-World Evidence). The C-RARE app consists of 9 tasks of Activities of Daily Living and socialization as well as three parent reported Sanfilippo specific questionnaires.

The objectives of this study are:

  • To enhance the understanding of the natural history and progression of MPS IIIC syndrome on behavior, cognitive abilities, mobility, vision, hearing, speech, and expressive and receptive language
  • To define and categorize clinical endpoints that may be used in future clinical trials

Enrollment

30 estimated patients

Sex

All

Ages

12+ months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of Sanfilippo syndrome type C disease by all of the following:

  • Deficiency in heparan-alpha-glucosaminide N-acetyltransferase enzyme activity
  • Has presented with signs/symptoms consistent with Sanfilippo syndrome type C, or, for individuals who have not presented with signs/symptoms of disease (eg, siblings of known patients), the determination of eligibility will be at the discretion of the Sponsor in conjunction with the site Investigator
  • Genomic DNA analysis demonstrating homozygous or compound heterozygous, pathogenic and/or potentially pathogenic variants in the HGSNAT gene
  • Accumulated GAG HS in urine
  • Written informed consent from parent or legal guardian and assent from patient, if required
  • Parent/legal guardian willing to accompany the patient to all study visits
  • Ability to comply with protocol requirements, in the opinion of the Investigator
  • Negative urine pregnancy test at screening (nonsterile females of childbearing potential only).

Functional abilities:

  • Able to take food or liquid by mouth, able to walk with or without assistance.
  • Has an age equivalent on the Vineland Adaptive Behavior Scales (VABS) of ≥1 year.

Exclusion criteria

Patients who meet any of the following criteria will not be eligible to participate in the study:

  • Have received an investigational drug within 30 days prior to the Baseline Visit
  • Concomitant illness or medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient's ability to comply with protocol requirements, the patient's well-being or safety, or the interpretability of the patient's clinical data
  • The presence of significant non-MPS IIIC-related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study

Trial design

30 participants in 3 patient groups

Retrospective and prospective observational study of patients living with MPS IIIC
Description:
Cohort 1: These participants will be a part of the retrospective and prospective Natural History Study, including the C-RARE video assessments. In clinic visits will include: neurocognitive, developmental and behavioral clinical outcome assessments as well as biochemical sample analysis, imaging measures and retrospective medical record review. Participants will record daily living activities through the C-RARE app on their mobile device.
Remote video recording study and retrospective medical chart review of patients living with MPS IIIC
Description:
Cohort 2: These participants will not attend in clinic visits. They will be a part of the C-RARE and retrospective medical chart review analysis. 35 patients with a confirmed diagnosis of MPS IIIC from English, Spanish and Portuguese speaking households will be recruited for this portion of the study.
Retrospective medical chart review of MPS IIIC patients either living or deceased
Description:
Cohort 3: Deceased or living medical record analysis only of patients with MPS IIIC. Living patients will not be participating in cohort 1 clinical study or cohort 2 C-RARE study.

Trial contacts and locations

2

Loading...

Central trial contact

Nathalie Guffon, MD; Nathalie Reynes

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems